ECSP22013340A - Métodos para preparar análogos de incretina - Google Patents

Métodos para preparar análogos de incretina

Info

Publication number
ECSP22013340A
ECSP22013340A ECSENADI202213340A ECDI202213340A ECSP22013340A EC SP22013340 A ECSP22013340 A EC SP22013340A EC SENADI202213340 A ECSENADI202213340 A EC SENADI202213340A EC DI202213340 A ECDI202213340 A EC DI202213340A EC SP22013340 A ECSP22013340 A EC SP22013340A
Authority
EC
Ecuador
Prior art keywords
preparing
methods
incretin analogs
incretin
analogs
Prior art date
Application number
ECSENADI202213340A
Other languages
English (en)
Inventor
Ankur Jalan
Michael E Kobierski
Michael E Kopach
Jinju James
Sergey Vladimirovich Tsukanov
Yu Lu
Timothy Donald White
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP22013340A publication Critical patent/ECSP22013340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen compuestos intermediarios para preparar análogos de incretina o sales farmacéuticamente aceptables de estos. Además, se describen métodos para preparar análogos de incretina mediante el acoplamiento de dos a cuatro de los compuestos intermediarios de la presente descripción mediante síntesis en fase híbrida sólida líquida o unión química nativa.
ECSENADI202213340A 2019-08-19 2022-02-18 Métodos para preparar análogos de incretina ECSP22013340A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962888756P 2019-08-19 2019-08-19

Publications (1)

Publication Number Publication Date
ECSP22013340A true ECSP22013340A (es) 2022-03-31

Family

ID=72322545

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202213340A ECSP22013340A (es) 2019-08-19 2022-02-18 Métodos para preparar análogos de incretina

Country Status (18)

Country Link
US (1) US20220411461A1 (es)
EP (1) EP4017866A1 (es)
JP (2) JP2022545200A (es)
KR (2) KR102812908B1 (es)
CN (1) CN114269775A (es)
AU (1) AU2020334993B2 (es)
BR (1) BR112022001081A2 (es)
CA (1) CA3148347A1 (es)
CL (3) CL2022000374A1 (es)
CO (1) CO2022001413A2 (es)
EC (1) ECSP22013340A (es)
IL (1) IL289957A (es)
MX (1) MX2022002115A (es)
MY (1) MY201700A (es)
PE (1) PE20221049A1 (es)
PH (1) PH12022550398A1 (es)
WO (1) WO2021034815A1 (es)
ZA (1) ZA202200948B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
AU2022269659B2 (en) 2021-05-07 2025-04-10 Eli Lilly And Company Erodible tablet
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
TW202404996A (zh) * 2022-04-04 2024-02-01 美商美國禮來大藥廠 製備glp-1/升糖素雙重促效劑之方法
CN115368234B (zh) * 2022-08-19 2024-01-26 淄博矿业集团有限责任公司 一种索马鲁肽侧链及其中间体的合成方法
IL320036A (en) * 2022-10-05 2025-06-01 Lilly Co Eli Peptides for incretin synthesis
KR20250110330A (ko) * 2022-11-21 2025-07-18 일라이 릴리 앤드 캄파니 Gip/glp1 이중 효능제의 제조 방법
CN119080910B (zh) * 2023-10-07 2025-08-15 北京泽勤生物医药有限公司 长效ggg三靶点激动剂
WO2025098464A1 (en) * 2023-11-10 2025-05-15 Innovent Biologics (Suzhou) Co., Ltd. Intermediate for preparing glucagon and glp-1 dual agonist and preparation method therefor
CN118546077A (zh) * 2024-05-15 2024-08-27 江苏诺泰澳赛诺生物制药股份有限公司 一种脂肪二酸片段的制备方法及应用
WO2026073030A1 (en) 2024-09-27 2026-04-02 Carmot Therapeutics Inc. Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists
CN119350469B (zh) * 2024-12-23 2025-05-23 杭州诺澳生物医药科技有限公司 大片段SPPS-LPPS混合法合成Cagrilintide的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006644A2 (en) * 2009-07-15 2011-01-20 Lonza Ltd Process for the production of exenatide and of an exenatide analogue
IN2014MN02304A (es) 2012-05-03 2015-08-07 Zealand Pharma As
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
SI3004155T1 (sl) * 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
CN103613656B (zh) * 2013-11-20 2015-03-04 陕西东大生化科技有限责任公司 一种艾塞那肽的固相片段合成方法
CN103864918B (zh) * 2014-03-31 2016-08-17 哈尔滨吉象隆生物技术有限公司 一种利拉鲁肽的固相合成方法
TWI582109B (zh) 2015-01-09 2017-05-11 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
ES2983409T3 (es) 2016-03-10 2024-10-23 Medimmune Ltd Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
CN106749610A (zh) * 2016-12-29 2017-05-31 陕西慧康生物科技有限责任公司 一种艾塞那肽的制备方法及其产品
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
KR20240051304A (ko) 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
TWI837615B (zh) * 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CA3223313A1 (en) * 2021-06-23 2022-12-29 Eli Lilly And Company Methods of using and compositions including an incretin analog

Also Published As

Publication number Publication date
CO2022001413A2 (es) 2022-03-18
AU2020334993B2 (en) 2023-07-13
IL289957A (en) 2022-03-01
KR20250074694A (ko) 2025-05-27
JP2024147650A (ja) 2024-10-16
MX2022002115A (es) 2022-03-17
US20220411461A1 (en) 2022-12-29
JP2022545200A (ja) 2022-10-26
PE20221049A1 (es) 2022-06-30
EP4017866A1 (en) 2022-06-29
BR112022001081A2 (pt) 2022-05-24
KR20220035199A (ko) 2022-03-21
CN114269775A (zh) 2022-04-01
CL2024003748A1 (es) 2025-04-04
CA3148347A1 (en) 2021-02-25
WO2021034815A1 (en) 2021-02-25
CL2022000374A1 (es) 2022-11-18
NZ785006A (en) 2025-09-26
ZA202200948B (en) 2024-09-25
CL2024003747A1 (es) 2025-03-28
PH12022550398A1 (en) 2023-10-23
MY201700A (en) 2024-03-13
KR102812908B1 (ko) 2025-05-28
AU2020334993A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
ECSP22013340A (es) Métodos para preparar análogos de incretina
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
AR118856A2 (es) Compuestos terapéuticos
GT201300207A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CR20120460A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales
CR20140301A (es) Derivados de betulina
CU20130129A7 (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
CR20160291A (es) Análogos de cortistatina y síntesis y usos de los mismos
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MD20180040A2 (ro) Inhibitori ai virusului hepatic C
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
CY1124608T1 (el) Παραγωγα φαινυλιου ως ρυθμιστες υποδοχεα pge2
BR112016013618A8 (pt) derivados de maleimida como moduladores de série de reação de wnt, seus usos, composição farmacêutica e processo para a preparação dos mesmos
PH12014500311A1 (en) Antiviral compounds with a fused tricyclic ring
CY1121147T1 (el) Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου
EA202091481A1 (ru) Замещенные алкиниленовые соединения в качестве противораковых агентов
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.
CU20220023A7 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR128996A1 (es) Procedimiento para preparar un agonista dual glp-1 / glucagón
CL2019002967A1 (es) Proceso para la preparación de piperazina para la síntesis de derivados de pirazinocarbazol.
MX2022002720A (es) Inhibidor de magl, procedimiento de preparacion y uso del mismo.
CY1115953T1 (el) Υποκατεστhμενες 2-(χρωμαν-6-υλοξυ)-θειαζολες και η χρηση τους ως φαρμακευτικες ουσιες